Phase I/II Intratumoral DC Immunotherapy With Gemcitabine & XRT in Unresectable Pancreatic Cancer

Trial ID or NCT#

NCT00547144

Status

not recruiting iconNOT RECRUITING

Purpose

To determine the safety, feasibility and appropriate dendritic cell dose to vaccinate patients with pancreas cancer

Official Title

A Phase I/II Trial of Intratumoral Dendritic Cell Immunotherapy in Combination With Gemcitabine and Stereotactic Radiosurgery in Unresectable Pancreatic Cancer

Eligibility Criteria

Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

George A Fisher
George A Fisher
Medical oncologist, Gastrointestinal specialist
Colleen Haas Chair in the School of Medicine, Emeritus

Contact us to find out if this trial is right for you.

Contact

Jenna Rogers
6507234467

View on ClinicalTrials.gov